Simbionix Acquires the ARTHRO VR Product Line by GMV

Simbionix Acquires the ARTHRO VR Product Line by GMV

PR Newswire

CLEVELAND, January 25, 2012 /PRNewswire/ —

Simbionix USA Corporation, the world’s leading provider of medical education and simulation training, is pleased to announce it has purchased the ARTHRO VR, a virtual reality arthroscopic training simulator line from GMV, Spain. This purchase expands the company’s training tools to provide clients with advanced solutions for orthopedic surgeons. As with all Simbionix training simulators, this system is the ideal complement to traditional training techniques, reducing instruction time and providing a complete hands-on experience.

In the coming years, all arthroscopic procedures are expected to grow considerably, as lifestyle choices nowadays include more sports and physical activities which tend to cause more injuries. In addition, the general population has a longer lifespan and older individuals are more susceptible to joint damage, further increasing the need for arthroscopic procedures. These continuing changes in demographic lifestyle choices are not only driving demand for arthroscopy from patients; they are leading more and more surgeons to seek out training in arthroscopic techniques. Compared to conventional open surgery, arthroscopic surgery performed by an experienced surgeon, holds numerous and well established benefits including small incisions with a reduced risk of infection and less pain.

ARTHRO VR is an advanced arthroscopic training simulator designed for the most effective acquisition of the skills required for arthroscopic surgery. The simulator features a line of simulated procedures, intelligently combining fiberglass limb replicas with 3D images and haptic sensation, to allow users to learn key aspects of the procedures. Simulated procedures are performed utilizing a realistic set of tools as used in the OR including the arthroscopic camera, which allow the trainee to acquire a true-to-life hands-on experience. Training modules in increasing difficulty include healthy anatomies and various pathologies, provide trainees with the opportunity to practice basic skills and master procedure skills. The product line offers educational aids such as panoramic views and a set of metrics for complete objective assessment of the learning process.

“Identified by Simbionix as a leading product line in a growing field, the ARTHRO VR is a well suited addition to our current line of industry leading simulators and integrates nicely with our global distribution channel,” said Gary Zamler, Simbionix CEO. “This purchase demonstrates our ongoing commitment to advancing medical education, and identifying high quality simulation technologies for our expanding global customer base. Simbionix will continue to invest resources in arthroscopy, enhancing available modules and growing the simulator lines capabilities. I would also like to express our appreciation to the GMV Management team for the cooperative spirit and manner in which we worked together so well over the past few months, leading to this desirable result.”

About Simbionix USA Corporation

Simbionix is the world’s leading provider of simulation, training and education products for medical professionals and the healthcare industry. The company is committed to delivering high quality products, advancing clinical performance and optimizing procedural outcomes.

Visit: http://www.simbionix.com

Contact: rebecca@simbionix.com

+1-216-2292040

About GMV

GMV is a multinational technology business group trading on a worldwide scale in industries such as Aerospace, Defense and Security, intelligent systems for Transportation, Telecommunications and ICT for Healthcare, public administration and large corporations. The company’s growth strategy is based on technological leadership and continuous innovation; 10% of its turnover is plowed back into R&D and holds several international patents.

Visit: http://www.gmv.com

Contact: mpozo@gmv.com

SOURCE Simbionix USA Corporation

Be the first to comment

Leave a Reply